Sexual Function during Long‐Term Duloxetine Treatment in Patients with Recurrent Major Depressive Disorder

In patients with MDD, the probability of continued or emergent SD after up to 34 weeks of open‐label duloxetine treatment was associated with the response status of the patients. In patients who responded to duloxetine treatment, after up to a further 52 weeks of double‐blind treatment either with duloxetine or placebo, the probability of continued or emergent SD appeared to be more related to MDD itself than the treatments that the patients received. Montejo A‐L, Perahia DGS, Spann ME, Wang F, Walker DJ, Yang CR, and Detke MJ. Sexual function during long‐term duloxetine treatment in patients with recurrent major depressive disorder.